Abstracts tagged "autoimmune diseases"

Abstract Number: 338 • 2012 ACR/ARHP Annual Meeting
The Potent Phosphoinositide-3-Kinase-(δ,γ) Inhibitor IPI-145 Is Active in Preclinical Models of Arthritis and Well Tolerated in Healthy Adult Subjects
James R. Porter¹, Janid Ali², Jonathan P. DiNitto², Joi Dunbar², Kerrie Faia², Jennifer Hoyt², Brianne Leary², Alice R. Lim², Christian Martin², Charlotte McKee², Patrick O'Hearn², Melissa Pink², Jennifer Proctor², John Soglia², Bonnie Tillotson², Kerry White², David G. Winkler² and Vito J. Palombella², ¹Product Development, Infinity Pharmaceuticals, Inc., Cambridge, MA, ²Infinity Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Phosphoinositide-3-kinases (PI3K) play pivotal roles in cell signaling and regulate a variety of cellular functions. PI3K-δ and PI3K-γ isoforms are necessary for adaptive and…
Abstract Number: 1820 • 2012 ACR/ARHP Annual Meeting
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Gardasil^®) and Autoimmune Disorders: Safety Assessment Using the Pharmacoepidemiologic General Research Extension System
Lamiae Grimaldi-Bensouda¹, Michel Rossignol², Elodie Aubrun¹, Pamela Leighton³, Didier Guillemot⁴, Alfred Mahr⁵, Jacques Benichou⁶, Paul-Henri Lambert⁷, Bertrand Godeau⁸ and Lucien Abenhaim⁹, ¹LA-SER, Paris, France, ²LA-SER, Centre for Risk Research, Montreal, Canada, ³LA-SER Europe Ltd., London, United Kingdom, ⁴Institut Pasteur (PhEMI)/ INSERM U657 & Université Paris-Ile de France Ouest, Paris, France, ⁵Internal Medicine, Hospital Saint-Louis, Paris, France, ⁶INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, Rouen, France, ⁷Centre of Vaccinology & neonatal immunology, University of Geneva, Geneva, Switzerland, ⁸Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ⁹LA-SER Europe Ltd, London, United Kingdom
Background/Purpose: This study investigated whether the human papillomavirus (HPV) vaccine [types 6, 11, 16, 18] is associated with a modified risk of autoimmune disorders (AIDs).…
Abstract Number: 341 • 2012 ACR/ARHP Annual Meeting
Oral Administration of a Novel Small Molecule BET Bromodomain Inhibitor, RVX-297, Reduces Disease Severity in a Rat Collagen-Induced Arthritis Model
R. Jahagirdar¹, S. Attwell¹, E.M. Gesner¹, K.G. McLure¹, H.C. Hansen¹, J. Chen², J. Wu¹, K. Norek¹, N. Shenoy², G.S. Wagner¹ and P. R. Young¹, ¹Resverlogix Corporation, Calgary, AB, Canada, ²Aravasc Inc., Sunnyvale, CA
Background/Purpose: BET (Bromodomain and Extra-Terminal) proteins have recently emerged as a key epigenetic regulator of genes at the transcriptional level and inhibition of their binding…
Abstract Number: 1671 • 2012 ACR/ARHP Annual Meeting
Characterization of Jo-1 Autoantibodies in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Kyle P. Chiang¹, Varun Gauba¹, Darin Lee¹, Minh-Ha T. Do¹, Jie J. Zhou², Feng Wang², Ying Buechler¹, Leslie Nangle¹, Zhiwen Xu², John Mendlein¹, Melissa Ashlock¹ and Jeffrey M. Greve¹, ¹aTyr Pharma, San Diego, CA, ²Scripps Laboratory, Institute for Advanced Study, Hong Kong University of Science and Technology, Kowloon, Hong Kong
Background/Purpose: Anti-Jo-1 autoantibodies (Jo-1 Abs), directed against histidine tRNA synthetase (HisRS1), are detected in a high proportion of patients with both autoimmune inflammatory myopathy (IM)…
Abstract Number: 196 • 2012 ACR/ARHP Annual Meeting
Sarcoidosis in Northern New England. Clinical Characteristics and Predictive Factors for More Aggressive Therapy
Alireza Meysami¹, Kevin F. Spratt² and Christopher M. Burns³, ¹Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Department of Orthopaedic Surgery, Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth Medical School, Lebanon, NH
· Background/Purpose: Sarcoidosis is characterized by a variable clinical presentation. DMARDs and biologics have been used for resistant and/or organ-threatening disease. We analyzed the cases…
Abstract Number: 1627 • 2012 ACR/ARHP Annual Meeting
New Insights Into the Presentation and the Management of Hepatitis B Reactivation in Patients with Autoimmune Diseases and Inflammatory Arthritis
Nina Droz¹, Laurent Gilardin², Patrice Cacoub Sr.³, Francis Berenbaum⁴, Daniel Wendling⁵, Bertrand Godeau⁶, Anne-Marie Piette⁷, Emmanuelle Dernis⁸, Mikael Ebbo⁹, Bruno Fautrel¹⁰, Arsène Meikinian¹¹, Aude Rigolet¹², Sophie Rivière¹³, Stanislas Pol¹⁴, Loic Guillevin¹⁵, Luc Mouthon¹⁶ and Benjamin Terrier¹⁷, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Internal Medicine, Saint Antoine Hospital, Paris, France, ³Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ⁴Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ⁵Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ⁶Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ⁷Internal Medicine, Foch Hospital, Suresnes, France, ⁸Centre Hospitalier, Le Mans, France, ⁹Internal Medicine, Conception Hospital, Marseille, France, ¹⁰Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ¹¹Internal Medicine, Jean Verdier Hospital, Bondy, France, ¹²Internal Medicine I & II, Pitie-Salpetriere Hospital, APHP, UPMC Paris VI, Paris, France, ¹³Internal Medicine, Lapeyronie, Montpellier, France, ¹⁴Hepatology, Cochin Hospital, Paris, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Internal Medicine, Hopital Cochin, Paris, France, ¹⁷Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: In patients with autoimmune diseases and inflammatory arthritis, immunosuppressive therapy may trigger Hepatitis B virus (HBV) reactivation, leading to significant morbidity and mortality. Objective.…
Abstract Number: 200 • 2012 ACR/ARHP Annual Meeting
Rheumatic Manifestations and Connective Tissue Diseases in Autoimmune Hepatitis of the Child and the Adult
Federico Zazzetti¹, Nora C. Fernandez², Javier Benavidez², Luis A. Colombato³, Graciela R. Rodriguez⁴, Graciela Nardi⁵, Carolina Bru Morón⁶, Oscar L. Rillo⁷, Nelo A. Quadrini⁸, Stella M. Garay⁹, Mariana Fabi⁹, Teresita Gonzalez¹⁰ and Juan C. Barreira¹¹, ¹Rheumatology, Buenos Aires Hospital Britanico, Buenos Aires, Argentina, ²Hepatology, Buenos Aires British Hospital, Buenos Aires, Argentina, ³Gastroenterology, Buenos Aires British Hospital, Buenos Aires, Argentina, ⁴Rheumatology, Hospital Dr. Ignacio Pirovano, Buenos Aires, Argentina, ⁵Gastroenterology, Hospital Dr. Ignacio Pirovano, Buenos Aires, Argentina, ⁶Rheumatology, Hospital Dr. Enrique Tornú, Buenos Aires, Argentina, ⁷Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁸Gastroenterology, Hospital Dr. Enrique Tornú, Buenos Aires, Argentina, ⁹Rheumatology, Hospital IAEP Sor María Ludovica, La Plata, Argentina, ¹⁰Hepatology, Hospital IAEP Sor María Ludovica, La Plata, Argentina, ¹¹Rheumatology, Buenos Aires British Hospital, Buenos Aires, Argentina
Background/Purpose: Autoimmune hepatitis (AIH) is a progressive fibrosing inflammatory disease of the liver of unknown etiology, leading to cirrhosis. Its course is usually fluctuating and…
Abstract Number: 1388 • 2012 ACR/ARHP Annual Meeting
Diagnostic Accuracy of Anti-dsDNA Antibodies in Unselected Patients with Recent Onset of Rheumatic Symptoms
Michele Compagno¹, Søren Jacobsen², Ole Petter Rekvig³, Lennart Truedsson⁴, Niels H. H. Heegaard⁵, Johannes C. Nossent⁶, Andreas Jönsen¹, Rasmus Sleimann Jacobsen⁷, Gro Østli Eilertsen⁶, Gunnar K. Sturfelt⁸ and Anders Bengtsson¹, ¹Department of clinical sciences - Rheumatology, Lund University, Lund, Sweden, ²Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³Department of Biochemistry and Medical Biology, University Hospital, Tromsø, Norway, ⁴Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ⁵Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ⁶Dept of Rheumatology, University of Tromsø, Tromso, Norway, ⁷Department of Infectious Diseases and Rheumatology, Section 4242, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁸Department of Rheumatology, University Hospital Lund, Lund, Sweden
Background/Purpose: Anti-dsDNA antibodies are widely used in diagnostic settings when SLE is suspected. Crithidia Luciliae Immunofluorescence Test (CLIFT) and Enzyme Linked ImmunoSorbent Assay (ELISA) are…
Abstract Number: 100 • 2012 ACR/ARHP Annual Meeting
Further Evidence On Biased Cancer Risk Estimation in Studies Comparing A Subpopulation to the General Population
Koray Tascilar¹ and Hasan Yazici², ¹University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey
Background/Purpose: We had previously proposed a selection bias in studies estimating cancer risk in patients with rheumatoid arthritis (RA) stemming from the comparison of a…
Abstract Number: 1391 • 2012 ACR/ARHP Annual Meeting
Anti-Ku Autoantibodies in Systemic Lupus Erythematosus Versus Autoimmune Myositis As Measured by a Novel Chemiluminescence Assay
Michael Mahler¹, Jason Wu², Magdalena Szmyrka-Kaczmarek³, Andreas Swart⁴, Marvin J. Fritzler⁵, Jean-Luc Senécal⁶ and John G. Hanly⁷, ¹Research, INOVA Diagnostics, San Diego, CA, ²Research, INOVA Diagnostics, San Diego, ³Rheumatology, Wroclaw Medical University, Wroclaw, Poland, ⁴Rheumatology clinic Neuss, Neuss, Germany, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada
Background/Purpose: Autoantibodies targeting Ku, an abundant nuclear protein with DNA helicase activity, have been reported in patients with systemic autoimmune rheumatic diseases. Little is known…
Abstract Number: 1308 • 2012 ACR/ARHP Annual Meeting
Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab : Data From the Autoimmunity and Rituximab Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Patrice Cacoub⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Xavier X. Le Loet¹¹, Eric Hachulla¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Gabriel Baron¹⁶ and Xavier Mariette¹⁷, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁶Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Rheumatology Department, CHU de ROUEN, Rouen, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology, Strasbourg, France, ¹⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Therapy with biological agents may be associated with opportunistic infections (OIs). Data on the occurrence of OIs in patients with RA treated with rituximab…
Abstract Number: 2682 • 2012 ACR/ARHP Annual Meeting
Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Systemic Lupus Erythematosus
Tomohiro Koga¹, Kunihiro Ichinose², Masayuki Mizui³, José C. Crispín⁴ and George C. Tsokos⁴, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with SLE exhibit abnormal signaling upon TCR engagement and have an altered gene expression profile. Accordingly, the regulation of several transcription factors…
Abstract Number: 1079 • 2012 ACR/ARHP Annual Meeting
Polyclonal CD4⁺Foxp3⁺treg Cells Induce TGFb-Dependent Tolerogenic Dendritic Cells That Suppress Murine Lupus-Like Syndrome
Qin Lan¹ and Song G. Zheng², ¹Medicine, University of Southern California, Los Angeles, CA, ²Medicine, Keck School of Medicine of USC, Los Angeles, CA
Background/Purpose: Interplay between Foxp3+ regulatory T cells (Treg) and dendritic cells (DCs) maintains immunologic tolerance, but the effects of each cell on the other are…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].